NFE2L2 and early-onset autosomal dominant Alzheimer disease: This review will discuss the evidence for activation of nuclear factor erythroid 2-related factor 2 (Nrf2) in neurodegeneration, pharmacological and genetic targeting of Nrf2, and in which cells Nrf2 is activated, focusing on Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease and multiple sclerosis.